762 related articles for article (PubMed ID: 25307450)
1. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.
Madic J; Kiialainen A; Bidard FC; Birzele F; Ramey G; Leroy Q; Rio Frio T; Vaucher I; Raynal V; Bernard V; Lermine A; Clausen I; Giroud N; Schmucki R; Milder M; Horn C; Spleiss O; Lantz O; Stern MH; Pierga JY; Weisser M; Lebofsky R
Int J Cancer; 2015 May; 136(9):2158-65. PubMed ID: 25307450
[TBL] [Abstract][Full Text] [Related]
2. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma.
Bidard FC; Madic J; Mariani P; Piperno-Neumann S; Rampanou A; Servois V; Cassoux N; Desjardins L; Milder M; Vaucher I; Pierga JY; Lebofsky R; Stern MH; Lantz O
Int J Cancer; 2014 Mar; 134(5):1207-13. PubMed ID: 23934701
[TBL] [Abstract][Full Text] [Related]
3. Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Riva F; Bidard FC; Houy A; Saliou A; Madic J; Rampanou A; Hego C; Milder M; Cottu P; Sablin MP; Vincent-Salomon A; Lantz O; Stern MH; Proudhon C; Pierga JY
Clin Chem; 2017 Mar; 63(3):691-699. PubMed ID: 28073896
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients.
Fernandez SV; Bingham C; Fittipaldi P; Austin L; Palazzo J; Palmer G; Alpaugh K; Cristofanilli M
Breast Cancer Res; 2014 Oct; 16(5):445. PubMed ID: 25307991
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions.
Saliou A; Bidard FC; Lantz O; Stern MH; Vincent-Salomon A; Proudhon C; Pierga JY
Expert Rev Mol Diagn; 2016; 16(1):39-50. PubMed ID: 26568208
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
[TBL] [Abstract][Full Text] [Related]
7. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
[TBL] [Abstract][Full Text] [Related]
8. Association between Mutation and Expression of
Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
[TBL] [Abstract][Full Text] [Related]
9. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
[TBL] [Abstract][Full Text] [Related]
10. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
[TBL] [Abstract][Full Text] [Related]
11. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
[TBL] [Abstract][Full Text] [Related]
12. Monitoring gastric cancer progression with circulating tumour DNA.
Hamakawa T; Kukita Y; Kurokawa Y; Miyazaki Y; Takahashi T; Yamasaki M; Miyata H; Nakajima K; Taniguchi K; Takiguchi S; Mori M; Doki Y; Kato K
Br J Cancer; 2015 Jan; 112(2):352-6. PubMed ID: 25490524
[TBL] [Abstract][Full Text] [Related]
13. A headlight on liquid biopsies: a challenging tool for breast cancer management.
Massihnia D; Perez A; Bazan V; Bronte G; Castiglia M; Fanale D; Barraco N; Cangemi A; Di Piazza F; Calò V; Rizzo S; Cicero G; Pantuso G; Russo A
Tumour Biol; 2016 Apr; 37(4):4263-73. PubMed ID: 26790442
[TBL] [Abstract][Full Text] [Related]
14. Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.
Parkinson CA; Gale D; Piskorz AM; Biggs H; Hodgkin C; Addley H; Freeman S; Moyle P; Sala E; Sayal K; Hosking K; Gounaris I; Jimenez-Linan M; Earl HM; Qian W; Rosenfeld N; Brenton JD
PLoS Med; 2016 Dec; 13(12):e1002198. PubMed ID: 27997533
[TBL] [Abstract][Full Text] [Related]
15. Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer.
Parsons HA; Beaver JA; Cimino-Mathews A; Ali SM; Axilbund J; Chu D; Connolly RM; Cochran RL; Croessmann S; Clark TA; Gocke CD; Jeter SC; Kennedy MR; Lauring J; Lee J; Lipson D; Miller VA; Otto GA; Rosner GL; Ross JS; Slater S; Stephens PJ; VanDenBerg DA; Wolff AC; Young LE; Zabransky DJ; Zhang Z; Zorzi J; Stearns V; Park BH
Clin Cancer Res; 2017 Jan; 23(2):379-386. PubMed ID: 27489289
[TBL] [Abstract][Full Text] [Related]
16. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.
Kim H; Kim YJ; Park D; Park WY; Choi DH; Park W; Cho WK; Kim N
Breast Cancer Res Treat; 2021 Aug; 189(1):167-175. PubMed ID: 34152505
[TBL] [Abstract][Full Text] [Related]
18. Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer.
Rossi G; Mu Z; Rademaker AW; Austin LK; Strickland KS; Costa RLB; Nagy RJ; Zagonel V; Taxter TJ; Behdad A; Wehbe FH; Platanias LC; Gradishar WJ; Cristofanilli M
Clin Cancer Res; 2018 Feb; 24(3):560-568. PubMed ID: 29180605
[No Abstract] [Full Text] [Related]
19. Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer.
De Luca F; Rotunno G; Salvianti F; Galardi F; Pestrin M; Gabellini S; Simi L; Mancini I; Vannucchi AM; Pazzagli M; Di Leo A; Pinzani P
Oncotarget; 2016 May; 7(18):26107-19. PubMed ID: 27034166
[TBL] [Abstract][Full Text] [Related]
20. Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients.
Liao H; Zhang J; Zheng T; Liu X; Zhong J; Shao B; Dong X; Wang X; Du P; King BL; Jia S; Yu J; Li H
J Transl Med; 2022 May; 20(1):211. PubMed ID: 35562750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
